tiprankstipranks
Shattuck Labs (STTK)
NASDAQ:STTK
US Market

Shattuck Labs (STTK) Stock News & Sentiment

173 Followers
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
PremiumPress Releases
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
2d ago
Shattuck Labs Reports Promising Cancer Trial Outcomes
PremiumCompany Announcements
Shattuck Labs Reports Promising Cancer Trial Outcomes
19d ago
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
PremiumPress Releases
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
19d ago
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
PremiumPress Releases
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
23d ago
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
PremiumPress Releases
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
27d ago
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress
PremiumPress Releases
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress
2M ago
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
PremiumPress Releases
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
2M ago
More STTK News >

News Score - Last 7 Days

Neutral
STTK
Sector Average
Media Buzz
This Week1 articles
Weekly Average2.5 articles
News Sentiment
This Week50%
Sector Average57%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is STTK’s Media Buzz Sentiment?
1 articles about STTK were published this week. In an average week, 2.5 articles are published.
    What is STTK’s weekly average amount of articles?
    In an average week, 2.5 articles about STTK are published.
      What is STTK’s News Sentiment?
      50% of articles about STTK were positive this week, compared to its sector average of 57%.
        Healthcare Stocks that are Trending in the News
        WBAWalgreens Boots Alliance
        LBPHLongboard Pharmaceuticals
        ELTPElite Pharmaceuticals
        DYAIDyadic International
        AFYAAfya
        Showing the stocks with the most bullish news sentiment over the past week
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis